Akari Therapeutics Plc price to book ratio AKTX
Market value divided by the book value of the company's net assets, since 2015.
- Today, Nov 2, 2026
- 32.8×
- 10-year median
- 0.1×
- Against its 10-year history
- 88th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 0.0× to 58.2×
- Peer median
- 2.6×
Akari Therapeutics Plc's price to book ratio is 32.8× as of Nov 2, 2026.
That is above its ten-year median of 0.1×, higher than on 88% of days in the last ten years.
Over that time it ranged from 0.0× in Mar 2018 to 58.2× in May 2026.
The median for 10 large drugmakers of a similar size is 2.6×.
Price to book ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 32.8× | 0.1× | 58.2× |
| 2025 | 0.4× | 0.4× | 2.0× |
| 2024 | n/m a value too high to mean anything | ||
| 2023 | n/m a value too high to mean anything | ||
| 2022 | n/m a value too high to mean anything | ||
| 2021 | n/m a value too high to mean anything | ||
| 2020 | n/m a value too high to mean anything | ||
| 2019 | n/m a value too high to mean anything | ||
| 2018 | 0.0× | 0.0× | 0.1× |
| 2017 | 0.1× | 0.0× | 0.3× |
| 2016 | 0.1× | 0.1× | 0.2× |
| 2015 | 0.2× | 0.0× | 0.3× |
Against its peers
Companies in Drug Manufacturers - General nearest Akari Therapeutics Plc's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| AKTXAkari Therapeutics Plc | 32.8× |
| ZVRAZevra Therapeutics | 2.8× |
| IRWDIronwood Pharmaceuticals | n/m |
| PBYIPuma Biotechnology | 3.8× |
| ARVNArvinas | 0.9× |
| COLLCollegium Pharmaceutical | 2.5× |
| ABUSArbutus Biopharma | 3.1× |
| CRMDCorMedix | 0.9× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OMEROmeros | n/m |
| ANABAnaptysbio | 132× |
| Peer median | 2.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Akari Therapeutics Plc
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.